The vaccine has been successfully tested on animals by a team at the University of Stanford and is now moving onto human trials.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated formula and delivery, NeoVax MI,is not only feasible and ...

Secondary infections caused by bacteria or viruses during hospital care remain a long-standing global challenge, despite ...

By Vijay Kumar Malesu A pioneering personalized mRNA vaccine study reveals lasting immune responses in triple-negative breast cancer, offering early signals that tailored cancer vaccination may help ...

Scientists in the Blavatnik Institute at Harvard Medical School and MIT have created a new family of tools that, for the ...

A detailed analysis of immune cells in Long COVID patients has revealed a previously unknown molecular signature linked to lingering symptoms. In Germany, Long COVID develops in up to about one in ten ...

A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...

Harmonizing immunophenotyping assay designs facilitates integrating findings across trials, enabling biomarker identification and validation, revealing cohort-specific features and drug mechanisms as ...

BOSTON – Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine ...